Article thumbnail

Phospho-ERK and AKT status, but not KRAS mutation status, are associated with outcomes in rectal cancer treated with chemoradiotherapy

By Janine M Davies, Dimitri Trembath, Allison M Deal, William K Funkhouser, Benjamin F Calvo, Timothy Finnegan, Karen E Weck, Joel E Tepper and Bert H O'Neil
Topics: Research
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2000). A: Specific c-K-ras gene mutations as a tumor-response marker in locally advanced rectal cancer treated with preoperative chemoradiotherapy. Ann Surg Oncol
  2. (2008). A: Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
  3. (2009). al: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
  4. (2004). al: High frequency of mutations of the PIK3CA gene in human cancers. Science
  5. (2007). Cantley LC: AKT/PKB signaling: navigating downstream. Cell
  6. (1995). CC: Tumor proliferation in rectal cancer following preoperative irradiation.
  7. (1999). Cell survival promoted by the Ras-MAPK signaling pathway by transcriptiondependent and -independent mechanisms. Science
  8. (2004). Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
  9. (2005). chromosomal instability and prognosis in colorectal cancer. Biochim Biophys Acta
  10. (2009). CJ: BRAF mutation in metastatic colorectal cancer.
  11. (2010). Conte PF: Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy.
  12. (2004). CR: Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res
  13. (2009). de Velde CJ, Marijnen CA: PIK3CA mutations predict local recurrences in rectal cancer patients. Clin Cancer Res
  14. (2002). Der CJ: Ras family signaling: therapeutic targeting. Cancer Biol Ther
  15. (2006). DS: Increased expression of pAKT is associated with radiation resistance in cervical cancer.
  16. (2009). Eckhardt SG: KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection.
  17. (2007). Edwards RH: Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma.
  18. (2010). Engelman JA: The PI3K pathway as drug target in human cancer.
  19. (2004). et al: Different genetic features associated with colon and rectal carcinogenesis. Clin Cancer Res
  20. (2009). et al: Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer. Ann Oncol
  21. (2010). et al: KRAS genotyping of paraffinembedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology.
  22. (2002). et al: Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin Cancer Res
  23. (2006). et al: Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma. J Clin Oncol
  24. (2009). et al: PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer.
  25. (2003). FA: Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer. Clin Cancer Res
  26. (2004). HA: Prognostic relevance of activated Akt kinase in node-negative breast cancer: a clinicopathological study of 99 cases. Mod Pathol
  27. (2004). Han ZC: Phosphatidylinositide 3-kinase/AKT in radiation responses. Histol Histopathol
  28. (2003). Increase of AKT/PKB expression correlates with gleason pattern in human prostate cancer.
  29. (2009). JM: Divergent oncogenic changes influence survival differences between colon and rectal adenocarcinomas. Dis Colon Rectum
  30. (2010). KM: Comparison of Sanger Sequencing, Pyrosequencing, and Melting Curve Analysis for the Detection of KRAS Mutations. Diagnostic and Clinical Implications.
  31. (2010). KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy. Radiother Oncol
  32. (1995). Krebs EG: The MAPK signaling cascade.
  33. (2006). LC: The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet
  34. (1990). Ling CC, Muschel RJ: The role of the H-ras oncogene in radiation resistance and metastasis.
  35. (2008). MR: Analysis of the K-ras/B-raf/Erk signal cascade, p53 and CMAP as markers for tumor progression in colorectal cancer patients. Oncol Rep
  36. (1999). PTEN gene transfer in human malignant glioma: sensitization to irradiation and CD95L-induced apoptosis. Oncogene
  37. (1988). Ras oncogene expression as a prognostic indicator in rectal adenocarcinoma.
  38. (2004). Segelov E: PTEN mutations are common in sporadic microsatellite stable colorectal cancer. Oncogene
  39. (2004). Soderkvist P: Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis
  40. (2008). Soong R: Detection of BRAF V600E mutation by pyrosequencing. Pathology
  41. (2007). Sugihara K: PIK3CA mutation is predictive of poor survival in patients with colorectal cancer.
  42. (2004). Velculescu VE: Oncogenic mutations of PIK3CA in human cancers. Cell Cycle
  43. (2000). WG: Direct evidence for the contribution of activated N-ras and K-ras oncogenes to increased intrinsic radiation resistance in human tumor cell lines. Cancer Res
  44. (2001). WG: Ras inhibitors and radiation therapy. Semin Radiat Oncol
  45. (2004). YS: BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res
  46. (2002). Zauber P: Is there a predictive value for molecular markers in predicting response to radiation and chemotherapy in rectal cancer?